AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study

About this update from Photocure Asa

[{"type":"text","content":"OSLO, Norway, May 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological Association Annual Congress (AUA) 2026. The first highlighted the benefits of Blue Light Cystoscopy (BLC®), notably its diagnostic sensitivity impacting the management of high-risk NMIBC* patients, helping urologists and patients make well-informed decisions. The second abstract investigated the impact of avoiding recurrence in a Blue Light versus White Light Cystoscopy (WLC) comparison of costs at 5 years. The AUA Annual Meeting 2026 was held May 15-18th in Washington DC, USA.","length":670,"tagName":"p"},{"type":"text","content":"In the Poster and Podiums session on Friday, May 15: IP20-24: "Blue Light Cystoscopy Enables Earlier CIS Recognition and Can Guide Risk-Appropriate Management of High-Risk Non–Muscle-Invasive Bladder Cancer: Real-World Outcomes from a U.S. Claims Cohort" by Mark D. Tyson","length":283,"tagName":"p"},{"type":"text","content":"The objective of this study was to evaluate whether blue light cystoscopy (BLC®) improves early recognition of CIS/high-risk disease and helps inform clinical decision making in real-world practice. The study looked at 794 BLC and 4,764 matched WLC patients from the Optum Research Database (2016–2023).","length":303,"tagName":"p"},{"type":"text","content":"Blue light cystoscopy (BLC) was found to significantly improve early detection of carcinoma in situ (CIS) and high-risk non–muscle-invasive bladder cancer compared to white light cystoscopy (WLC) using claims from the OPTUM database.","length":233,"tagName":"p"},{"type":"text","content":"Specific findings include:","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BLC was associated with significantly higher CIS detection (8.5% vs. 3.4%) and cystectomy rates (4.6% vs. 2.3%)","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased Bacillus Calmette-Guérin (BCG) therapy use (31.0% vs. 15.9%) that persisted over approximately 3.5 years of follow-up","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"These differences remained significant beyond the initial 90 days, indicating durable diagnostic sensitivity and facilitating earlier, risk-appropriate treatment decisions, whi...

More updates from Photocure Asa